NASDAQ:ITCI Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis $69.56 +0.49 (+0.71%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$68.16▼$69.7250-Day Range$64.96▼$76.5852-Week Range$45.50▼$84.89Volume467,100 shsAverage Volume1.04 million shsMarket Capitalization$7.34 billionP/E RatioN/ADividend YieldN/APrice Target$94.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Intra-Cellular Therapies alerts: Email Address Intra-Cellular Therapies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside35.6% Upside$94.33 Price TargetShort InterestHealthy3.53% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment1.15Based on 3 Articles This WeekInsider TradingSelling Shares$1.86 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.51) to $0.93 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.87 out of 5 starsMedical Sector34th out of 879 stocksPharmaceutical Preparations Industry10th out of 417 stocks 4.4 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageIntra-Cellular Therapies has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Intra-Cellular Therapies' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.53% of the outstanding shares of Intra-Cellular Therapies have been sold short.Short Interest Ratio / Days to CoverIntra-Cellular Therapies has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intra-Cellular Therapies has recently decreased by 6.75%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for Intra-Cellular Therapies is -1.23. Previous Next 2.9 News and Social Media Coverage News SentimentIntra-Cellular Therapies has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Intra-Cellular Therapies this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for ITCI on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows4 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,855,393.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intra-Cellular Therapies' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.51) to $0.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -59.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -59.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 11.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Intra-Cellular Therapies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About Intra-Cellular Therapies Stock (NASDAQ:ITCI)Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Read More ITCI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITCI Stock News HeadlinesJune 26, 2024 | insidertrades.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Director Rory B. Riggs Sells 4,462 SharesJune 25, 2024 | insidertrades.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Director Nostrand Robert L. Van Sells 20,000 SharesJuly 8, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” July 4, 2024 | americanbankingnews.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest UpdateJuly 1, 2024 | americanbankingnews.comBrokerages Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $94.33June 19, 2024 | seekingalpha.comIntra-Cellular Brightens MDD Outlook With Caplyta SuccessJune 18, 2024 | gurufocus.comWhat's Driving Intra-Cellular Therapies Inc's Surprising 15% Stock Rally?June 18, 2024 | benzinga.comIntra-Cellular Therapies' Highlights Successful Data From Second Depression StudyJuly 8, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” June 18, 2024 | globenewswire.comIntra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive DisorderJune 10, 2024 | globenewswire.comIntra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare ConferenceMay 30, 2024 | investorplace.comThe Secret Stock Stash: 3 Overlooked Picks That Belong in Every PortfolioMay 29, 2024 | ca.finance.yahoo.comITCI Aug 2024 65.000 putMay 29, 2024 | globenewswire.comIntra-Cellular Therapies to Present at the Jefferies Global Healthcare ConferenceMay 23, 2024 | globenewswire.comIntra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual MeetingMay 10, 2024 | markets.businessinsider.comMaintained Buy Rating on ITCI Shares Amidst Strong Caplyta Revenue and Positive MDD Study OutlookMay 8, 2024 | finance.yahoo.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comIntra-Cellular Therapies Inc (ITCI) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...See More Headlines Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/07/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ITCI CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees610Year FoundedN/APrice Target and Rating Average Stock Price Target$94.33 High Stock Price Target$120.00 Low Stock Price Target$77.00 Potential Upside/Downside+35.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,670,000.00 Net Margins-21.57% Pretax Margin-21.38% Return on Equity-18.49% Return on Assets-15.26% Debt Debt-to-Equity RatioN/A Current Ratio5.12 Quick Ratio5.00 Sales & Book Value Annual Sales$464.37 million Price / Sales15.81 Cash FlowN/A Price / Cash FlowN/A Book Value$6.15 per share Price / Book11.31Miscellaneous Outstanding Shares105,570,000Free Float101,985,000Market Cap$7.34 billion OptionableOptionable Beta1.01 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Sharon Mates Ph.D. (Age 71)Co-Founder, Chairman & CEO Comp: $2.23MMr. Michael I. Halstead J.D. (Age 51)President Comp: $983.65kDr. Suresh K. Durgam M.D. (Age 55)Executive VP & Chief Medical Officer Comp: $961.84kMr. Mark Neumann (Age 61)EVP & Chief Commercial Officer Comp: $998.36kDr. Robert E. Davis Ph.D. (Age 73)Senior VP & Chief Scientific Officer Comp: $646.12kMr. Juan Fernando Sanchez (Age 53)Vice President of Corporate Communications & Investor Relations Comp: $296.75kMs. Karen Patruno Sheehy Esq. (Age 62)Senior VP & Chief Compliance Officer Dr. Michael OlchaskeySenior VP & Head of Regulatory AffairsMr. John A. BardiSenior VP of Market Access, Policy & Government AffairsDr. Willie R. Earley M.D.Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsViela BioNASDAQ:VIERa PharmaceuticalsNASDAQ:RARXAimmune TherapeuticsNASDAQ:AIMTKura OncologyNASDAQ:KURAIronwood PharmaceuticalsNASDAQ:IRWDView All CompetitorsInsiders & InstitutionsDNB Asset Management ASBought 13,402 shares on 7/5/2024Ownership: 0.076%First Hawaiian BankBought 493 shares on 7/2/2024Ownership: 0.006%Rory B RiggsSold 4,462 sharesTotal: $337,193.34 ($75.57/share)Nostrand Robert L VanSold 20,000 sharesTotal: $1.52 M ($75.91/share)Teachers Retirement System of The State of KentuckySold 660 shares on 5/28/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions ITCI Stock Analysis - Frequently Asked Questions How have ITCI shares performed this year? Intra-Cellular Therapies' stock was trading at $71.62 at the beginning of the year. Since then, ITCI stock has decreased by 2.9% and is now trading at $69.56. View the best growth stocks for 2024 here. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings data on Tuesday, May, 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.15. The company's quarterly revenue was up 52.0% on a year-over-year basis. Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' top institutional shareholders include DNB Asset Management AS (0.08%) and First Hawaiian Bank (0.01%). Insiders that own company stock include Sharon Mates, Rory B Riggs, Joel S Marcus, Mark Neumann, Michael Halstead, Suresh K Durgam, Nostrand Robert L Van and Lawrence J Hineline. View institutional ownership trends. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV) and Novavax (NVAX). This page (NASDAQ:ITCI) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
